October 3 - 5, 2019


The Motif

Seattle, WA

CME/CE Credit

We are in the process of putting together the 15th Annual (2019) Coastal Dermatology Symposium program. 
Please SIGN UP for email updates to keep informed of program developments for our upcoming conference as they become available.





Dermatologists, dermatology residents, family practitioners, physician assistants, nurse practitioners, nurses, and other healthcare professionals who treat diseases of the skin.


After completing this live activity, participants should be better able to:

  • Design a comprehensive treatment plan for acne, rosacea and contact dermatitis patients based on clinical guidelines, incorporating pharmacologic and nonpharmacologic strategies.
  • Identify risk factors and design treatment plans for actinic keratosis and seborrheic keratosis.
  • Differentiate and develop treatment plans for actinic keratosis, and seborrheic keratosis.
  • Describe the pathophysiology of psoriasis and the associated comorbidities of the disease.
  • Diagnose and treat patients with psoriasis appropriately, based on current clinical guidelines.
  • Design treatment strategies that incorporate biologic therapies in the management of appropriately selected patients with psoriasis.
  • Incorporate strategies for use of new therapies aimed at blocking the inflammatory mediators of atopic dermatitis, both mild to moderate and moderate to severe.
  • Integrate checklists, evaluation tools, and dermoscopy into examination of suspect skin lesions to produce an accurate diagnosis and guide treatment decisions.
  • Distinguish key characteristics of emerging and newly approved agents for treating skin infections
  • Describe the evolving pathophysiology and effects of chronic itch on quality of life.  
  • Identify and treat onychomycosis and tinea in appropriately selected patients.
  • Design treatment strategies appropriate for pediatric patients with common dermatologic conditions.
  • Identify characteristics in pediatric patients that suggest increased risk for conversion of benign moles to dysplastic nevi or melanoma.

Follow Us

Jointly Provided By